8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney Disease [EPPIC] trials) examined AST-120's efficacy in slowing CKD progression. This study assessed the efficacy of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials.

          Related collections

          Author and article information

          Journal
          BMC Nephrol
          BMC nephrology
          1471-2369
          1471-2369
          Sep 30 2016
          : 17
          : 1
          Affiliations
          [1 ] Vanderbilt University School of Medicine, Nashville, TN, USA.
          [2 ] University of Colorado Health Sciences Center, Denver, CO, USA.
          [3 ] Cleveland Clinic Foundation, Cleveland, OH, USA.
          [4 ] Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
          [5 ] IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
          [6 ] Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
          [7 ] University of Heidelberg, Heidelberg, Germany.
          [8 ] Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
          [9 ] Kureha Corporation, 3-26-2, Hyakunin-cho, Shinjuku-ku, Tokyo, 169-8503, Japan.
          [10 ] Kureha Corporation, 3-26-2, Hyakunin-cho, Shinjuku-ku, Tokyo, 169-8503, Japan. mami-k@kureha.co.jp.
          Article
          10.1186/s12882-016-0357-9
          10.1186/s12882-016-0357-9
          5045594
          27716149
          d7d10568-51e5-431e-badf-867dd8bc5e95
          History

          AST-120,Chronic kidney disease,Clinical trial,Spherical carbon adsorbent,Uremic toxin

          Comments

          Comment on this article